Skip to main content
Premium Trial:

Request an Annual Quote

PacBio Signs On Brazilian Distributor for PacBio RS II Platform

NEW YORK (GenomeWeb News) – Pacific Biosciences today announced a distribution deal covering the newly launched PacBio RS II in Brazil.

Under the terms of the deal, PacBio's first distribution agreement in South America, Uniscience do Brasil will exclusively distribute the next-generation sequencing platform in Brazil. PacBio RS II was launched last month. It generates finished genome assemblies, elucidates epigenomes, and characterizes genomic variation, PacBio said.

The platform is based on the Menlo Park, Calif.-based firm's Single Molecule, Real-
Time DNA Sequencing technology, allowing it to generate average read lengths of 5,000 base pairs, "with the longest reads above 20,000 base pairs in length with double the throughput from the previous version of the system," the firm said.

Terms of the deal were not disclosed.

Last week, PacBio partnered with Sage Science to co-market Sage's BluePippin DNA size selection tool for use with the PacBio RS II platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.